, Volume 64, Issue 3, pp 245–275 | Cite as

Drug-Induced Renal Calculi

Epidemiology, Prevention and Management
  • Michel Daudon
  • Paul Jungers
Review Article


Drug-induced calculi represent 1–2% of all renal calculi. The drugs reported to produce calculi formation may be divided into two groups.

The first one includes poorly soluble drugs with high urine excretion that favours crystallisation in the urine. Among poorly soluble molecules, triamterene was the leading cause of drug-containing urinary calculi in the 1970s, and it is still currently responsible for a significant number of calculi. In the last decade, drugs used for the treatment of HIV-infected patients, namely indinavir and sulfadiazine, have become the most frequent cause of drug-containing urinary calculi. Besides these drugs, about twenty other molecules may induce nephrolithiasis in patients receiving long-term treatment or high doses. Calculi analysis by physical methods, including infrared spectroscopy or x-ray diffraction, is needed to demonstrate the presence of the drug or its metabolites within the calculi.

The second group includes drugs that provoke urinary calculi as a consequence of their metabolic effects. Here, diagnosis relies on careful clinical inquiry because physical methods are ineffective to differentiate between urinary calculi induced by the metabolic effects of a drug and common metabolic calculi. The incidence of such calculi, especially those resulting from calcium/vitamin D supplementation, is probably underestimated.

Although drug-induced urinary calculi most often complicate high-dose, long-duration drug treatments, there also exist specific patient risk factors in relation to urine pH, urine output and other parameters, which provide a basis for preventive or curative treatment of calculi.

Better awareness of the possible occurrence of lithogenic complications, preventive measures based on drug solubility characteristics and close surveillance of patients on long-term treatment with drugs with lithogenic potential, especially those with a history of urolithiasis, should reduce the incidence of drug-induced nephrolithiasis.


Allopurinol Indinavir Nephrolithiasis Calcium Oxalate Renal Calculus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.


  1. 1.
    Antopol W, Robinson H. Urolithiasis and renal pathology after administration of sulfapyridine. Proc Soc Exp Biol Med 1939; 40: 428–39Google Scholar
  2. 2.
    Barnes RW, Kawaichi GK. Factors influencing the formation of sulfonamide urinary concretions. J Urol 1943; 49: 324–30Google Scholar
  3. 3.
    Sulfamidothérapie intestinale. In: Abaza A. Acquisitions médicales récentes dans les pays alliés. Paris: Doin & Cie, 1946: 260–83Google Scholar
  4. 4.
    Lawrence JS, Francis J, Sorsby A, et al. The sulphonamides and antibiotics in man and animals. London: Lewis HK & Co Ltd, 1953Google Scholar
  5. 5.
    Lehr D. Clinical toxicity of sulfonamides. Ann N Y Acad Sci 1957; 69: 417–47PubMedCrossRefGoogle Scholar
  6. 6.
    Curtis JR. Drug-induced renal disease. Drugs 1979; 18(5): 377–91PubMedCrossRefGoogle Scholar
  7. 7.
    Daudon M, Protat MF, Réveillaud RJ. Detection and diagnosis of drug-induced urinary calculi [in French]. Ann Biol Clin (Paris) 1983; 41(4): 239–49Google Scholar
  8. 8.
    Réveillaud RJ, Daudon M. Drug-induced urinary lithiasis [in French]. Presse Med 1983; 12(38): 2389–92PubMedGoogle Scholar
  9. 9.
    Cifuentes Delatte L. Composicion y estructura de los calculos renales. Madrid: Salvat, 1984Google Scholar
  10. 10.
    Daudon M, Réveillaud RJ. Drug nephrolithiasis: an unrecognized and underestimated pathology. In: Schwille PO, Smith LH, Robertson WG, et al., editors. Urolithiasis and related clinical Research. New York: Plenum Press, 1985: 371–4CrossRefGoogle Scholar
  11. 11.
    Réveillaud RJ, Daudon M. Les lithiases urinaires médicamenteuses. Semin Uro-Nephrol 1986; 12: 14–39Google Scholar
  12. 12.
    Rapado A, Traba ML, Caycho C, et al. Drug-induced renal stones: incidence, clinical expression and stone analysis. Contrib Nephrol 1987; 58: 25–9PubMedGoogle Scholar
  13. 13.
    Daudon M, Estepa L. Drug induced lithiases [in French]. Presse Med 1998; 27(14): 675–83PubMedGoogle Scholar
  14. 14.
    Daudon M. Drug-induced urinary calculi in 1999 [in French]. Prog Urol 1999; 9(6): 1023–33PubMedGoogle Scholar
  15. 15.
    Watson RA, Ettinger B, Deshon Jr GE, et al. Triamterene stone: advantage of crystallographic analysis. Urology 1981; 18(3): 238–40PubMedCrossRefGoogle Scholar
  16. 16.
    Daudon M, Bader CA, Jungers P. Urinary calculi: review of classification methods and correlations with etiology. Scanning Microsc 1993; 7: 1081–106PubMedGoogle Scholar
  17. 17.
    Nguyen Quy D, Daudon M. Infrared and raman spectra of calculi. Paris: Elsevier, 1997Google Scholar
  18. 18.
    Daudon M, Réveillaud RJ. Drug-induced crystalluria: myths and realities [in French]. Ann Biol Clin 1986; 44(1): 25–34Google Scholar
  19. 19.
    Daudon M. Méthodes d’analyse des calculs et des cristaux urinaires: classification morpho-constitutionnelle des calculs. In: Jungers P, Daudon M, Le Duc A, editors. Lithiase urinaire. Paris: Flammarion Médecine-Sciences, 1989: 35–113Google Scholar
  20. 20.
    Perazella MA. Crystal-induced acute renal failure. Am J Med 1999 Apr; 106: 459–65PubMedCrossRefGoogle Scholar
  21. 21.
    Gagnon RF, Tsoukas CM, Watters AK. Light microscopy of indinavir urinary crystals [letter]. Ann Intern Med 1998; 128(4): 321PubMedGoogle Scholar
  22. 22.
    Cohen-Solal F, Abdelmoula J, Hoarau MP, et al. Urinary lithiasis of medical origin [in French]. Therapie 2001; 56(6): 743–50PubMedGoogle Scholar
  23. 23.
    Daudon M, Réveillaud RJ, Normand M, et al. Piridoxilateinduced calcium oxalate calculi: a new drug-induced metabolic nephrolithiasis. J Urol 1987; 138(2): 258–61PubMedGoogle Scholar
  24. 24.
    Ettinger B, Oldroyd NO, Sorgel F. Triamterene nephrolithiasis. JAMA 1980; 244(21): 2443–5PubMedCrossRefGoogle Scholar
  25. 25.
    Asper R. Iatrogenic urinary calculi: detection and identification by X-ray diffraction. Clin Chem 1986; 24: 767–8Google Scholar
  26. 26.
    Ettinger B, Weil E, Mandel NS, et al. Triamterene-induced nephrolithiasis. Ann Intern Med 1979; 91(5): 745–6PubMedGoogle Scholar
  27. 27.
    Socolow EL. Triamterene-induced nephrolithiasis [letter]. Ann Intern Med 1980; 92(3): 437PubMedGoogle Scholar
  28. 28.
    Baudin S, Rodrigue H. Drug induced nephrolithiasis: observation of an oxalate and hydroxylated triamterene stone [in French]. Néphrologie 1980; 1(4): 183–5PubMedGoogle Scholar
  29. 29.
    Gault MH, Snedden W, Taor RE, et al. Triamterene urolithiasis. CMAJ 1981; 124(12): 1556–7Google Scholar
  30. 30.
    Grunberg RW, Silberg SJ. Triamterene-induced nephrolithiasis. JAMA 1981; 245(24): 2494–5PubMedCrossRefGoogle Scholar
  31. 31.
    Daudon M, Protat MF, Réveillaud RJ. Triamterene and renal calculi [in French]. Néphrologie 1982; 3(3): 119–23PubMedGoogle Scholar
  32. 32.
    Moesch C, Rincé M, Raby C, et al. Analysis of triamterene induced renal stones [in French]. J Pharm Clin 1989; 18: 87–95Google Scholar
  33. 33.
    Carey RA, Beg MM, McNally CF, et al. Triamterene and renal lithiasis: a review. Clin Ther 1984; 6(3): 302–9PubMedGoogle Scholar
  34. 34.
    Ettinger B. Risk of kidney stones [letter]. JAMA 1982; 248(16): 1971PubMedCrossRefGoogle Scholar
  35. 35.
    Woolfson RG, Mansell MA. Does triamterene cause renal calculi? BMJ 1991 Nov; 303: 1217–8PubMedCrossRefGoogle Scholar
  36. 36.
    Carr MC, Prien Jr EL, Babayan RK. Triamterene nephrolithiasis: renewed attention is warranted. J Urol 1990; 144(6): 1339–40PubMedGoogle Scholar
  37. 37.
    Sorgel F, Ettinger B, Benet LZ. The true composition of kidney stones passed during triamterene therapy. J Urol 1985; 134(5): 871–3PubMedGoogle Scholar
  38. 38.
    Sabot JF, Bernard P, Pinatel H, et al. Analysis of urinary calculi containing triamterene: presence of a glucuronic metabolite. Anal Lett 1996, 27Google Scholar
  39. 39.
    Pruitt A, Winkel J, Dayton P. Variations in the fate of triamterene. Clin Pharmacol Ther 1977; 21: 610–9PubMedGoogle Scholar
  40. 40.
    Sorgel F, Ettinger B, Benet LZ. Metabolic fate and solubility of triamterene: not an explanation for triamterene nephrolithiasis. J Pharm Sci 1986; 75(2): 129–32PubMedCrossRefGoogle Scholar
  41. 41.
    Fairley KF, Birch DF, Haines I. Abnormal urinary sediment in patients on triamterene. Lancet 1983; I: 421–2CrossRefGoogle Scholar
  42. 42.
    Fairley KF, Woo KT, Birch DF, et al. Triamterene-induced crystalluria and cylindruria: clinical and experimental studies. Clin Nephrol 1986; 26: 169–73PubMedGoogle Scholar
  43. 43.
    Farge D, Turner MW, Roy DR, et al. Dyazide-induced reversible acute renal failure associated with intracellular crystal deposition. Am J Kidney Dis 1986; 8(6): 445–9PubMedGoogle Scholar
  44. 44.
    Roy LF, Villeneuve JP, Dumont A, et al. Irreversible renal failure associated with triamterene. Am J Nephrol 1991; 11: 486–8PubMedCrossRefGoogle Scholar
  45. 45.
    Jick H, Dinan BJ, Hunter JR. Triamterene and renal stones. J Urol 1982; 127(2): 224–5PubMedGoogle Scholar
  46. 46.
    Ettinger B. Excretion of triamterene and its metabolite in triamterene stone patients. J Clin Pharmacol 1985; 25(5): 365–8PubMedGoogle Scholar
  47. 47.
    Kau S. Handling of triamterene by the isolated perfused rat kidney. J Pharmacol Exp Ther 1978; 206: 701–9PubMedGoogle Scholar
  48. 48.
    Sica DA, Gehr TW. Triamterene and the kidney. Nephron 1989; 51(4): 454–61PubMedCrossRefGoogle Scholar
  49. 49.
    Jungers P, Daudon M. Formes cliniques de la lithiase urinaire: lithiases médicamenteuses. In: Jungers P, Daudon M, Le Duc A, editors. Lithiase urinaire. Paris: Flammarion Médecine-Sciences, 1989: 408–16Google Scholar
  50. 50.
    White DJ, Nancollas GH. Triamterene and renal stone formation. J Urol 1982; 127(3): 593–7PubMedGoogle Scholar
  51. 51.
    Werness PG, Bergert JH, Smith LH. Triamterene urolithiasis: solubility, pk, effect on crystal formation, and matrix binding of triamterene and its metabolites. J Lab Clin Med 1982; 99(2): 254–62PubMedGoogle Scholar
  52. 52.
    Lynn K, Bailey R, Swainson C, et al. Renal failure with potassium-sparing diuretics. N Z Med J 1985; 98: 629–33PubMedGoogle Scholar
  53. 53.
    Favre L, Glasson P, Valotton M. Reversible acute renal failure from combined triamterene and indomethacin. Ann Intern Med 1982; 96: 317–20PubMedGoogle Scholar
  54. 54.
    Weinberg M, Quigg R, Salant D, et al. Anuric renal failure precipitated by indomethacin and triamterene. Nephron 1985; 40: 216–8PubMedCrossRefGoogle Scholar
  55. 55.
    Estepa-Maurice L, Hennequin C, Marfisi C, et al. Fourier transform infrared microscopy identification of crystal deposits in tissues: clinical importance in various pathologies. Am J Clin Pathol 1996; 105: 576–82PubMedGoogle Scholar
  56. 56.
    Spence JD, Wong DG, Lindsay RM. Effects of triamterene and amiloride on urinary sediment in hypertensive patients taking hydrochlorothiazide. Lancet 1985; II(8446): 73–5CrossRefGoogle Scholar
  57. 57.
    Bartlett JG. Protease inhibitors for HIV infection. Ann Intern Med 1996; 124(12): 1086–8PubMedGoogle Scholar
  58. 58.
    Deeks SG, Smith M, Holodniy M, et al. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997; 277(2): 145–53PubMedCrossRefGoogle Scholar
  59. 59.
    European Agency for the Evaluation of Medicinal Products. Commission decision of 4 October 1996 granting the marketing authorization for the medicinal product for human use, ‘CRIXIVAN® — Indinavir’. London: European Agency for the Evaluation of Medicinal Products, 1996Google Scholar
  60. 60.
    Merck & Co. Crixivan (indinavir sulphate) [Product monograph]. West Point (PA): Merck & Co., 1997Google Scholar
  61. 61.
    Herman JS, Ives NJ, Nelson M, et al. Incidence and risk factors for the development of indinavir-associated renal complications. J Antimicrob Chemother 2001; 48(3): 355–60PubMedCrossRefGoogle Scholar
  62. 62.
    Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997; 127: 119–25PubMedGoogle Scholar
  63. 63.
    Hermieu JF, Prevot MH, Ravery V, et al. Nephritic colic due to indinavir [in French]. Presse Med 1998; 27(10): 465–7PubMedGoogle Scholar
  64. 64.
    Piroth L, Grappin M, Waldner A, et al. Discontinuation of protease inhibitors due to intolerance: a longitudinal study in 309 HIV-1 positive patients [in French]. Presse Med 1999; 28(8): 381–7PubMedGoogle Scholar
  65. 65.
    Boubaker K, Sudre P, Bally F, et al. Changes in renal function associated with indinavir. AIDS 1998; 12(18): F249–54PubMedCrossRefGoogle Scholar
  66. 66.
    Reiter WJ, Schon-Pernerstorfer H, Dorfinger K, et al. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. J Urol 1999; 161(4): 1082–4PubMedCrossRefGoogle Scholar
  67. 67.
    Gulick RM, Mellors JW, Havlir D, et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000; 133(1): 35–9PubMedGoogle Scholar
  68. 68.
    Saltel E, Angel JB, Futter NG, et al. Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. J Urol 2000; 164(6): 1895–7PubMedCrossRefGoogle Scholar
  69. 69.
    Hermieu J, Prevot M, Ravery V, et al. Urolithiasis and the protease inhibitor indinavir. Eur Urol 1999; 35(3): 239–41PubMedCrossRefGoogle Scholar
  70. 70.
    Gentle DL, Stoller ML, Jarrett TW, et al. Protease inhibitor-induced urolithiasis. Urology 1997; 50(4): 508–11PubMedCrossRefGoogle Scholar
  71. 71.
    Sundaram CP, Saltzman B. Urolithiasis associated with protease inhibitors. J Endourol 1999; 13(4): 309–12PubMedCrossRefGoogle Scholar
  72. 72.
    Kohan AD, Armenakas NA, Fracchia JA. Indinavir urolithiasis: an emerging cause of renal colic in patients with human immunodeficiency virus. J Urol 1999; 161(6): 1765–8PubMedCrossRefGoogle Scholar
  73. 73.
    Blake SP, McNicholas MMJ, Raptopoulos V. Nonopaque crystal deposition causing ureteric obstruction in patients with HIV undergoing indinavir therapy. AJR Am J Roentgenol 1998; 171(3): 717–20PubMedGoogle Scholar
  74. 74.
    Schwartz BF, Schenkman N, Armenakas NA, et al. Imaging characteristics of indinavir calculi. J Urol 1999; 161(4): 1085–7PubMedCrossRefGoogle Scholar
  75. 75.
    Kopp JB. Renal dysfunction in HIV-1-infected patients. Curr Infect Dis Rep 2002; 4(5): 449–60PubMedCrossRefGoogle Scholar
  76. 76.
    Kopp JB, Falloon J, Fili A, et al. Indinavir-associated with interstitial nephritis and urothelial inflammation: clinical and cytologic findings. Clin Infect Dis 2002; 34(8): 1122–8PubMedCrossRefGoogle Scholar
  77. 77.
    Van Glabeke E, Conort P, Chartier-Kastler E, et al. Treatment of complicated renal colic in patients treated with indinavir: value of double J stents [in French]. Prog Urol 1999; 9(3): 470–3PubMedGoogle Scholar
  78. 78.
    Martinez E, Leguizamon M, Mallolas J, et al. Influence of environmental temperature on incidence of indinavir-related nephrolithiasis. Clin infect Dis 1999; 29(2): 422–5PubMedCrossRefGoogle Scholar
  79. 79.
    Bach MC, Godofski EW. Indinavir nephrolithiasis in warm climates. J AIDS Hum Pathol 1997; 14: 296–7Google Scholar
  80. 80.
    Tashima KT, Horowitz J, Rosen S. Indinavir nephropathy. N Engl J Med 1997; 336: 138–40PubMedCrossRefGoogle Scholar
  81. 81.
    van Rossum AM, Dieleman JP, Fraaij PL, et al. Indinavir-associated asymptomatic nephrolithiasis and renal cortex atrophy in two HIV-1 infected children. AIDS 2001; 15(13): 1745–7PubMedCrossRefGoogle Scholar
  82. 82.
    Reilly RF, Tray K, Perazella MA. Indinavir nephropathy revisited: a pattern of insidious renal failure with identifiable risk factors. Am J Kidney Dis 2001; 38(4): E23PubMedCrossRefGoogle Scholar
  83. 83.
    Berns JS, Cohen RM, Silverman M, et al. Acute renal failure due to indinavir crystalluria and nephrolithiasis: report of two cases. Am J Kidney Dis 1997; 30(4): 558–60PubMedCrossRefGoogle Scholar
  84. 84.
    Martinez F, Mommeja-Marin H, Estepa-Maurice L, et al. Indinavir crystal deposits associated with tubulointerstitial nephropathy. Nephrol Dial Transplant 1998; 13(3): 750–3PubMedCrossRefGoogle Scholar
  85. 85.
    Grabe DW, Eisele G, Miller C, et al. Indinavir-induced nephropathy. Clin Nephrol 1999; 51(3): 181–3PubMedGoogle Scholar
  86. 86.
    Jaradat M, Phillips C, Yum MN, et al. Acute tubulointerstitial nephritis attributable to indinavir therapy [letter]. Am J Kidney Dis 2000; 35(4): E16PubMedCrossRefGoogle Scholar
  87. 87.
    Anglicheau D, Duvic C, Nedelec G. Sudden anuria due to indinavir crystalluria. Nephron 2000; 86(3): 364–5PubMedCrossRefGoogle Scholar
  88. 88.
    Sarcletti M, Petter A, Romani N, et al. Pyuria in patients treated with indinavir is associated with renal dysfunction. Clin Nephrol 2000; 54(4): 261–70PubMedGoogle Scholar
  89. 89.
    Perazella MA, Kashgarian M, Cooney E. Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria. Clin Nephrol 1998; 50: 194–6PubMedGoogle Scholar
  90. 90.
    van Rossum AM, Dieleman JP, Fraaij PL, et al. Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir [letter]. Pediatrics 2002; 110 (2 Pt 1): e19PubMedCrossRefGoogle Scholar
  91. 91.
    Daudon M, Estepa L, Viard JP, et al. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet 1997; 349(9061): 1294–5PubMedCrossRefGoogle Scholar
  92. 92.
    Balani SH, Arison BH, Mathai L, et al. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab Dispos 1995; 23: 266–70PubMedGoogle Scholar
  93. 93.
    Chen IW, Vastag KJ, Lin JH. High-performance liquid Chromatographic determination of a potent and selective HIV protease inhibitor (L-735,524) in rat, dog and monkey plasma. J Chromatogr B Biomed Appl 1995; 672: 111–7PubMedCrossRefGoogle Scholar
  94. 94.
    Yeh KC, Deutsch PJ, Haddix H, et al. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother 1998; 42(2): 332–8PubMedGoogle Scholar
  95. 95.
    Hortin GL, King C, Miller KD, et al. Detection of indinavir crystals in urine: dependence on method of analysis. Arch Pathol Lab Med 2000; 124(2): 246–50PubMedGoogle Scholar
  96. 96.
    Rickerts V, Kober A, Stille W. Kristallurie und Nephrolithiasis bei Therapie mit dem Protease-Inhibitor Indinavir [letter]. Dtsch Med Wochenschr 1997; 122(24): 803PubMedGoogle Scholar
  97. 97.
    Gagnon RF, Tecimer SN, Watters AK, et al. Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. Am J Kidney Dis 2000; 36(3): 507–15PubMedCrossRefGoogle Scholar
  98. 98.
    Daudon M, Estepa L, Viard JP, et al. Indinavir crystalluria in HIV-positive patients treated with indinavir sulfate. In: Rodgers AL, Hibbert BE, Hess B, et al., editors. Urolithiasis 2000. Vol. I. Rondebosh: University of Cape Town, 2000: 335–7Google Scholar
  99. 99.
    Daudon M, Estepa L, Viard JP, et al. Épidémiologie et facteurs de risque des complications lithiasiques de l’indinavir. Feuill Biol 2001; 42(242): 31–4Google Scholar
  100. 100.
    Famularo G, Di Toro S, Moretti S, et al. Symptomatic crystalluria associated with indinavir. Ann Pharmacother 2000; 34(12): 1414–8PubMedCrossRefGoogle Scholar
  101. 101.
    Daudon M, Estepa L, Kebede M, et al. Urinary calculi and crystalluria in HIV+ patients treated with indinavir sulfate [in French]. Presse Med 1997; 26(34): 1612–5PubMedGoogle Scholar
  102. 102.
    Hanabusa H, Tagami H, Hataya H. Renal atrophy associated with long-term treatment with indinavir. N Engl J Med 1999; 340(5): 392–3PubMedCrossRefGoogle Scholar
  103. 103.
    Brodie SB, Keller MJ, Ewenstein BM, et al. Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients. AIDS 1998; 12(18): 2433–7PubMedCrossRefGoogle Scholar
  104. 104.
    Ascher DP, Lucy MD. Indinavir sulfate renal toxicity in a pediatric hemophiliac with HIV infection. Ann Pharmacother 1997; 31(10): 1146–9PubMedGoogle Scholar
  105. 105.
    Malavaud B, Dinh B, Bonnet E, et al. Increased incidence of indinavir nephrolithiasis in patients with hepatitis B or C virus infection. Antivir Ther 2000; 5(1): 3–5PubMedGoogle Scholar
  106. 106.
    Dieleman JP, Sturkenboom MC, Jambroes M, et al. Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort. Arch Intern Med 2002; 162(13): 1493–501PubMedCrossRefGoogle Scholar
  107. 107.
    Meraviglia P, Angeli E, Del Sorbo F, et al. Risk factors for indinavir-related renal colic in HIV patients: predictive value of indinavir dose/body mass index. AIDS 2002; 16(15): 2089–93PubMedCrossRefGoogle Scholar
  108. 108.
    Dieleman JP, Gyssens IC, van der Ende ME, et al. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999; 13(4): 473–8PubMedCrossRefGoogle Scholar
  109. 109.
    Rebassa Llull MJ, Conte Visus A, Grases Freixedas F, et al. Anuria in HIV+ patients treated with indinavir [in Spanish]. Arch Esp Urol 2000; 53(8): 719–21PubMedGoogle Scholar
  110. 110.
    Kalaitzis C, Dimitriadis G, Tsatidis T, et al. Treatment of indinavir sulfate induced urolithiasis in HIV-positive patients. Int Urol Nephrol 2002; 34(1): 13–5PubMedCrossRefGoogle Scholar
  111. 111.
    Wu DS, Stoller ML. Indinavir urolithiasis. Curr Opin Urol 2000; 10(6): 557–61PubMedCrossRefGoogle Scholar
  112. 112.
    Grases F, Costa-Bauza A, Garcia-Gonzalez R, et al. Indinavir crystallization and urolithiasis. Int Urol Nephrol 1999; 31(1): 23–9PubMedCrossRefGoogle Scholar
  113. 113.
    Verdon R, Daudon M, Albessard F, et al. Indinavir-induced cholelithiasis in a patient infected with human immunodeficiency virus. Clin Infect Dis 2002; 35(5): e57–9PubMedCrossRefGoogle Scholar
  114. 114.
    Burger DM, Hugen PW, Aamoutse RE, et al. A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy. J Acquir Immune Defic Syndr 2001; 26(3): 218–24PubMedCrossRefGoogle Scholar
  115. 115.
    Engeler DS, John H, Rentsch KM, et al. Nelfinavir urinary stones. J Urol 2002; 167(3): 1384–5PubMedCrossRefGoogle Scholar
  116. 116.
    Trolliet P, Dijoud F, Cotte L, et al. Crescentic glomerulonephritis and crystals within glomerular capillaries in an AIDS patient treated with foscarnet. Am J Nephrol 1995; 15: 256–9PubMedCrossRefGoogle Scholar
  117. 117.
    Maurice-Estepa L, Daudon M, Katlama C, et al. Identification of crystals in kidneys of AIDS patients treated with foscarnet. Am J Kidney Dis 1998; 32(3): 392–400PubMedCrossRefGoogle Scholar
  118. 118.
    Peterslund NA, Larsen ML, Mygind H. Acyclovir crystalluria. Scand J Infect Dis 1988; 20(2): 225–8PubMedCrossRefGoogle Scholar
  119. 119.
    Sawyer MH, Webb DE, Balow JE, et al. Acyclovir-induced renal failure: clinical course and histology. Am J Med 1988; 84(6): 1067–71PubMedCrossRefGoogle Scholar
  120. 120.
    Bianchetti MG, Roduit C, Oetliker OH. Acyclovir-induced renal failure: course and risk factors. Pediatr Nephrol 1991; 5: 238–9PubMedCrossRefGoogle Scholar
  121. 121.
    Becker BN, Fall P, Hall C, et al. Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature. Am J Kidney Dis 1993; 22: 611–5PubMedGoogle Scholar
  122. 122.
    Fogazzi GB. Crystalluria: a neglected aspect of urinary sediment analysis. Nephrol Dial Transplant 1996; 11(2): 379–87PubMedCrossRefGoogle Scholar
  123. 123.
    Newman HR, Shleser IH. Sulfonamide renal calculus. J Urol 1942; 47: 258–9Google Scholar
  124. 124.
    Schreiner GE, Maher JF. Toxic nephropathy. Am J Med 1965; 38: 409–49PubMedCrossRefGoogle Scholar
  125. 125.
    Albala DM, Prien Jr EL, Galal HA. Urolithiasis as a hazard of sulfonamide therapy. J Endourol 1994; 8(6): 401–3PubMedCrossRefGoogle Scholar
  126. 126.
    Diaz F, Collazos J, Mayo J,et al. Sulfadiazine-induced multiple urolithiasis and acute renal failure in a patient with AIDS and Toxoplasma encephalitis. Ann Pharmacother 1996; 30(1): 41–2PubMedGoogle Scholar
  127. 127.
    Goadsby PJ, Donaghy AJ, Lloyd AR, et al. Acquired immunodeficiency syndrome (AIDS) and s0ulfadiazine-associated acute renal failure. Ann Intern Med 1987; 107(5): 783–4PubMedGoogle Scholar
  128. 128.
    Sahai J, Heimberger T, Collins K, et al. Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder. Am J Med 1988; 84(4): 791–2PubMedCrossRefGoogle Scholar
  129. 129.
    Christin S, Baumelou A, Bahri S, et al. Acute renal failure due to sulfadiazine in patients with AIDS. Nephron 1990; 55(2): 233–4PubMedCrossRefGoogle Scholar
  130. 130.
    Hein R, Brunkhorst R, Thon WF, et al. Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases. Clin Nephrol 1993; 39(5): 254–6PubMedGoogle Scholar
  131. 131.
    Kronawitter U, Jakob K, Zoller WG, et al. Acute kidney failure caused by sulfadiazine stones: a complication of the therapy of toxoplasmosis in AIDS [in German]. Dtsch Med Wochenschr 1993; 118(46): 1683–6PubMedCrossRefGoogle Scholar
  132. 132.
    Marques LP, Madeira EP, Santos OR. Renal alterations induced by sulfadiazine therapy in an AIDS patients. Clin Nephrol 1994; 42(1): 68–9PubMedGoogle Scholar
  133. 133.
    Furrer H, von Overbeck J, Jaeger P, et al. Sulfadiazine nephrolithiasis and nephropathy [in German]. Schweiz Med Wochenschr 1994; 124(46): 2100–5PubMedGoogle Scholar
  134. 134.
    Potter JL, Kofron WG. Sulfadiazine/N4-acetylsulfadiazine crystalluria in a patient with the acquired immune deficiency syndrome (AIDS). Clin Chim Acta 1994; 230(2): 221–4PubMedCrossRefGoogle Scholar
  135. 135.
    Farina LA, Palou Redorta J, Chechile Toniolo G. Reversible acute renal failure due to sulfonamide-induced lithiasis in an AIDS patient. Arch Esp Urol 1995; 48(4): 418–9PubMedGoogle Scholar
  136. 136.
    Rodriguez-Carballeira M, Casagran A, More J, et al. Acute renal insufficiency caused by a sulfadiazine in a patient with cerebral toxoplasmosis and AIDS [in Spanish]. Enferm Infecc Microbiol Clin 1996; 14(2): 125–7PubMedGoogle Scholar
  137. 137.
    Crespo M, Quereda C, Pascual J, et al. Patterns of sulfadiazine acute nephrotoxicity. Clin Nephrol 2000; 54(1): 68–72PubMedGoogle Scholar
  138. 138.
    Sillar DB, Kleinig D. Sulphur calculi from ingestion of sulphasalazine. Br J Urol 1993; 71(6): 750–1PubMedCrossRefGoogle Scholar
  139. 139.
    Erturk E, Casemento JB, Guertin KR, et al. Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy. J Urol 1994; 151(6): 1605–6PubMedGoogle Scholar
  140. 140.
    Yanagisawa R, Kamijo T, Nagase Y. A case of drug induced urolithiasis composed of acetyl sulphapyridine associated with ulcerative colitis [in Japanese]. Nippon Hinyokika Gakkai Zasshi 1999; 90(3): 462–5PubMedGoogle Scholar
  141. 141.
    Russinko PJ, Agarwal S, Choi MJ, et al. Obstructive nephropathy secondary to sulfasalazine calculi. Urology 2003; 62(4): 748PubMedCrossRefGoogle Scholar
  142. 142.
    Dorfman LE, Smith JP. Sulfonamide crystalluria: a forgotten disease. J Urol 1970; 104(3): 482–3PubMedGoogle Scholar
  143. 143.
    Daudon M, Protat MF, Réveillaud RJ, et al. Study of spontaneous crystalluria by infrared spectroscopy: search for correlations between crystals, calculi, bacteria and the sex of the patients [in French]. Ann Biol Clin (Paris) 1983; 41: 199–207Google Scholar
  144. 144.
    Siegel WH. Unusual complication of therapy with sulfamethoxazole-trimethoprim. J Urol 1977; 117(3): 397PubMedGoogle Scholar
  145. 145.
    Karcher G, Tammen H, Martin C. Healing of a chronic therapyresistant urinary tract infection, complicated by bladder calculi and bladder inflow obstruction with Bactrim. Case report [in German]. Med Welt 1972; 23(39): 1363–4PubMedGoogle Scholar
  146. 146.
    Bülow H, Klee WE, Hotzel A, et al. Zur Frage einer Harnsteinbildung nach Trimethoprim Sulfamethoxazol-Therapie. Fortsch Urol Nephrol 1977; 9: 116–9CrossRefGoogle Scholar
  147. 147.
    Bulkova T, Kladensky J, Pacik D, et al. Drug-induced urolithiasis caused by N4-acetylsulfamethoxazole (Biseptol) and oxolinic acid (Desurol) [in Czech]. Rozhl Chir 1992; 71(11): 615–23PubMedGoogle Scholar
  148. 148.
    Rincé M, Dudognon P, Moesch C, et al. Urinary lithiasis induced by sulfamethoxazole in a patient with tetraplegia: case report. Paraplegia 1992; 30(10): 750–1PubMedCrossRefGoogle Scholar
  149. 149.
    Otto H, Allesch V. Urinary concrements due to long-term sulfonamides [in German]. Urologe 1969; 8(4): 202–4PubMedGoogle Scholar
  150. 150.
    Neal Jr MP. General case of the day. Sulfonamide crystallization in nonalkalinized urine. Radiographics 1988; 8(5): 993–6PubMedGoogle Scholar
  151. 151.
    Whiting F, Connell R, Forman SA. Silica urolithiasis in beef cattle: the incidence on different rations and on range. Can J Comp Med Vet Sci 1958; 22: 332–7PubMedGoogle Scholar
  152. 152.
    Daudon M, Estepa L, Labro B, et al. Infrared analysis of urinary calculi from animals [in French]. Eurobiol 1998; 236: 243–55Google Scholar
  153. 153.
    Hammarsten G, Helldorff I, Magnusson W, et al. Dubbelsidiga njurstenar av kiselsyra efter bruk av silikathaltigt antacidum. Svensk Lakartiduing 1953; 50: 1242–6Google Scholar
  154. 154.
    Hammarsten G. Terapi-inducerade urinvOagskonkrement. Opusc Med 1958; 3(1): 19–22Google Scholar
  155. 155.
    Herman JR, Goldberg AS. New type of urinary calculus caused by antacid therapy. JAMA 1960 Oct; 174: 1206–7PubMedCrossRefGoogle Scholar
  156. 156.
    Lagergren C. Development of silica calculi after oral administration of magnesium trisilicate. J Urol 1962; 87(6): 994–6PubMedGoogle Scholar
  157. 157.
    Lipworth E, Bloomberg BM, Reid FP. Urinary calculi containing silica: a case report. S Afr Med J 1964; 50(1): 50–1Google Scholar
  158. 158.
    Joekes AM, Rose GA, Sutor J. Multiple renal silica calculi. BMJ 1973; 1(846): 146–7PubMedCrossRefGoogle Scholar
  159. 159.
    Medina JA, Rodriguez J, Santos M, et al. Siliceous renal calculi in a man (11th case in the world) [in Spanish]. Rev Clin Esp 1978; 151(5): 411–3PubMedGoogle Scholar
  160. 160.
    Levison DA, Crocker PR, Banim S, et al. Silica stones in the urinary bladder. Lancet 1982; I(8274): 704–5CrossRefGoogle Scholar
  161. 161.
    Farrer JH, Rajfer J. Silicate urolithiasis. J Urol 1984; 132(4): 739–40PubMedGoogle Scholar
  162. 162.
    Irisawa C, Suzuki K, Nakagawa H, et al. Silicate urolithiasis: a case report [in Japanese]. Hinyokika Kiyo 1991; 37(3): 267–71PubMedGoogle Scholar
  163. 163.
    Irani J, Doré B, Bon D, et al. Silica urinary calculi: report of a case [in French]. Prog Urol 1992; 2(2): 290–3PubMedGoogle Scholar
  164. 164.
    Cruz Guerra NA, Gomez Garcia MA, Lovaco Castellano F, et al. Silica urolithiasis: report of a new case [in Spanish]. Actas Urol Esp 2000; 24(2): 202–4PubMedGoogle Scholar
  165. 165.
    Augusti M, Mikaelian JC, Monsaint H, et al. A silica urinary calculus secondary to the absorption of gelopectose in a child [in French]. Prog Urol 1993; 3(5): 812–5PubMedGoogle Scholar
  166. 166.
    Page RC, Heffner RR, Frey A. Urinary excretion of silica in humans following oral administration of magnesium trisilicate. Am J Dig Dis 1941; 8(1): 13–5CrossRefGoogle Scholar
  167. 167.
    Bailey CB. Silica excretion in cattle fed a ration predisposing to silica urolithiasis: total excretion and diurnal variations. Am J Vet Res 1967; 28(127): 1743–9PubMedGoogle Scholar
  168. 168.
    Gutierrez C, Padron M, Banares A, et al. Urinary retention in two male dromedaries due to silica uroliths. Zentralbl Veterinarmed A 1999; 46(9): 523–6PubMedGoogle Scholar
  169. 169.
    Osborne CA, Hammer RF, Klausner JS. Canine silica urolithiasis. J Am Vet Med Assoc 1981; 178(8): 809–13PubMedGoogle Scholar
  170. 170.
    Manning RA, Blaney BJ. Identification of uroliths by infrared spectroscopy. Aust Vet J 1986; 63(12): 393–6PubMedGoogle Scholar
  171. 171.
    Forman SA, Whiting F, Connell R. Silica urolithiasis in beef cattle: 3. chemical and physical composition of the uroliths. Can J Comp Med 1959; 23(4): 157–62PubMedGoogle Scholar
  172. 172.
    Bailey CB. The precipitation of polymerized silicic acid by urine protein: a possible mechanism in the etiology of silica urolithiasis. Can J Biochem 1972; 50(3): 305–11PubMedCrossRefGoogle Scholar
  173. 173.
    Aldrich J, Ling GV, Ruby AL, et al. Silica-containing urinary calculi in dogs (1981–1993). J Vet Intern Med 1997; 11(5): 288–95PubMedCrossRefGoogle Scholar
  174. 174.
    Singh SV, Khan MF, Rahman Q. Interaction of silica with plasma proteins: in vivo studies. Toxicol Letters 1985; 28(2-3): 89–92CrossRefGoogle Scholar
  175. 175.
    Emerick RJ. Phosphate inhibition of protein-polysilicic acid complex formation in vitro: a factor in preventing silica urolithiasis. J Nutr 1987; 117(11): 1924–28PubMedGoogle Scholar
  176. 176.
    AngwafoIII FF, Daudon M, Wonkam A, et al. Pediatric urolithiasis in sub-Saharan Africa: a comparative study in two regions of Cameroon. Eur Urol 2000; 37: 106–11PubMedCrossRefGoogle Scholar
  177. 177.
    Gault MH, Campbell NR, Aksu AE. Spurious stones. Nephron 1988; 48(4): 274–9PubMedCrossRefGoogle Scholar
  178. 178.
    Sabot JF, Bornet CE, Favre S, et al. The analysis of peculiar urinary (and other) calculi: an endless source of challenge. Clin Chim Acta 1999; 283(1–2): 151–8PubMedCrossRefGoogle Scholar
  179. 179.
    Alpaugh HB, Johnson FB. Silicon dioxide calculi in humans in the absence of silicate antacid medication. Scan Electron Microsc 1986; Pt (2): 969–72Google Scholar
  180. 180.
    Gaultier M, Bismuth C, Efthymiou ML, et al. Néphropathie tubulo-interstitielle aiguë au cours d’une intoxication par la glafénine [letter]. Nouv Presse Med 1975; 1: 3125Google Scholar
  181. 181.
    Réveillaud RJ, Daudon M, Protat MF, et al. Renal pelvis stones made of glafenic acid in two patients under prolonged treatment with analgesics (author’s translation) [in French]. Nephrologie 1980; 1(1): 3–8PubMedGoogle Scholar
  182. 182.
    Daudon M, Protat MF, Réveillaud RJ. Renal toxicity of glafenine in man: renal stones and acute renal failure [in French]. Ann Biol Clin (Paris) 1983; 41(2): 105–11Google Scholar
  183. 183.
    Pasquier B, Griffa N, Heritier P, et al. Urinary calculi caused by glaphenine: role of radiology in diagnosis: apropos of a case [in French]. J Radiol 1989; 70(6–7): 423–5PubMedGoogle Scholar
  184. 184.
    Moesch C, Daudon M, Leymarie J, et al. Glaphenine-containing gallstones. Eur J Chem Clin Biochem 1993; 31(5): 329–33Google Scholar
  185. 185.
    Daudon M, Moesch C, Marty L, et al. Antrafénine: calculs urinaires et cristalluries. Thérapie 1986; 41: 499–504PubMedGoogle Scholar
  186. 186.
    Moesch C, Rincé M, Raby C, et al. Identification d’un metabolite de la floctafénine dans un calcul urinaire. Ann Biol Clin (Paris) 1987; 45: 546–50Google Scholar
  187. 187.
    Landgrebe AR, Nyhan WL, Coleman M. Urinary-tract stones resulting from the excretion of oxypurinol. N Engl J Med 1975; 292(12): 626–7PubMedCrossRefGoogle Scholar
  188. 188.
    Greene ML, Fujimoto WY, Seegmiller JE. Urinary xanthine stones: a rare complication of allopurinol therapy. N Engl J Med 1969; 280(8): 426–7PubMedCrossRefGoogle Scholar
  189. 189.
    Sperling O, Brosh S, Boer P, et al. Urinary xanthine stones in an allopurinol-treated gouty patient with partial deficiency of hypoxanthine-guanine phosphoribosyltransferase. Isr J Med Sci 1978; 14(2): 288–92PubMedGoogle Scholar
  190. 190.
    Brock WA, Golden J, Kaplan GW. Xanthine calculi in the Lesch-Nyhan syndrome. J Urol 1983; 130(1): 157–9PubMedGoogle Scholar
  191. 191.
    Loris Pablo C, Olivan del Cacho MJ, Heras Gironella M, et al. Xanthine lithiasis in a case of Lesch-Nyhan syndrome treated with allopurinol [in Spanish]. An Esp Pediatr 1983; 19(5): 401–4PubMedGoogle Scholar
  192. 192.
    Kranen S, Keough D, Gordon RB, et al. Xanthine-containing calculi during allopurinol therapy. J Urol 1985; 133(4): 658–9PubMedGoogle Scholar
  193. 193.
    Oka T, Utsunomiya M, Ichikawa Y, et al. Xanthine calculi in the patient with the Lesch-Nyhan syndrome associated with urinary tract infection. Urol Int 1985; 40(3): 138–40PubMedCrossRefGoogle Scholar
  194. 194.
    Volpe P, Peyrottes A, Lammle M, et al. Calcul urinaire de xanthine chez un patient porteur d’un syndrome de Lesh Nyhan: a propos d’un cas. Prog Urol 1997; 7(1): 74–7PubMedGoogle Scholar
  195. 195.
    Stote RM, Smith LH, Dubb JW, et al. Oxypurinol nephrolithiasis in regional enteritis secondary to allopurinol therapy. Ann Intern Med 1980; 92(3): 384–5PubMedGoogle Scholar
  196. 196.
    Potter JL, Silvidi AA. Xanthine lithiasis, nephrocalcinosis, and renal failure in a leukemia patient treated with allopurinol. Clin Chem 1987; 33(12): 2314–6PubMedGoogle Scholar
  197. 197.
    Rincé C, Daudon M, Moesch C, et al. Identification of flumequine in a urinary calculus. J Clin Chem Clin Biochem 1987; 25: 313–4PubMedGoogle Scholar
  198. 198.
    Cifuentes I, Bellanato J, Arquillué A, et al. Presencia de acido oxolinico en un calculo renal. Arch Esp Urol 1986; 39(5): 369–73PubMedGoogle Scholar
  199. 199.
    Daudon M, Réveillaud RJ, Laurence C, et al. Drug-induced oxolinic acid crystalluria and nephrolithiasis [letter]. Clin Nephrol 1987; 28(3): 156PubMedGoogle Scholar
  200. 200.
    Chopra N, Fine PL, Price B, et al. Bilateral hydronephrosis from ciprofloxacin induced crystalluria and stone formation. J Urol 2000; 164(2): 438PubMedCrossRefGoogle Scholar
  201. 201.
    Najjar MF, Rammah M, Oueslati A, et al. Apport de la spectrophotométrie infrarouge dans l’analyse des calculs urinaires. Le Biologiste 1988; 22: 215–20Google Scholar
  202. 202.
    Cochat P, Cochat N, Jouvenet M, et al. Ceftriaxone-associated nephrolithiasis. Nephrol Dial Transplant 1990; 5(11): 974–6PubMedCrossRefGoogle Scholar
  203. 203.
    Dulac Y, Bouissou F, Azéma C, et al. Anuria caused by urinary lithiasis induced by ceftriaxone in a 6-year-old child [in French; letter]. Presse Med 1995; 24(19): 916PubMedGoogle Scholar
  204. 204.
    Feher G, Benczik A, Szabo E, et al. Renal gravel formation inducing renal insufficiency as a side-effect of ceftriaxon [in Hungarian]. Orv Hetil 1999; 140(14): 769–71PubMedGoogle Scholar
  205. 205.
    de Moor RA, Egberts AC, Schroder CH. Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis. Eur J Pediatr 1999; 158(12): 975–7PubMedCrossRefGoogle Scholar
  206. 206.
    Mulvaney WP, Beck CW, Brown RR. Urinary phenazopyridine stones: a complication of therapy. JAMA 1972; 221: 1511–2PubMedCrossRefGoogle Scholar
  207. 207.
    Crawford ED, Mulvaney WP. Rapid increase in calculous size: a possible hazard of phenazopyridine hydrochloride therapy in the presence of already formed stones. J Urol 1978; 119(2): 280–1PubMedGoogle Scholar
  208. 208.
    Schaad UB, Wedgwood-Krucko J, Tschaeppeler H. Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet 1988; II(8625): 1411–3CrossRefGoogle Scholar
  209. 209.
    Lopez AJ, O’Keefe P, Morrissey M, et al. Ceftriaxone-induced cholelithiasis. Ann Intern Med 1991; 115(9): 712–4PubMedGoogle Scholar
  210. 210.
    Kearney DK, O’Donnell D. Iatrogenic gallstones: a ceftriaxone complication. Australas Radiol 1998; 42: 236–7PubMedCrossRefGoogle Scholar
  211. 211.
    Ko CW, Sekijima JH, Lee SP. Biliary sludge. Ann Intern Med 1999; 130 Pt 1: 301–11Google Scholar
  212. 212.
    Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics. Drug Saf 1995; 13(6): 343–58PubMedCrossRefGoogle Scholar
  213. 213.
    Thorsteinsson SB, Bergan T, Oddsdottir S, et al. Crystalluria and ciprofloxacin, influence of urinary pH and hydration. Chemotherapy 1986; 32: 408–17PubMedCrossRefGoogle Scholar
  214. 214.
    Thorsteinsson SB, Bergan T, Rohwedder R. Tolerance of intravenously administered ciprofloxacin. Chemotherapy 1988; 34: 256–60PubMedCrossRefGoogle Scholar
  215. 215.
    Rippelmeyer DJ, Synhavsky A. Ciprofloxacin and allergic interstitial nephritis [letter]. Ann Intern Med 1988; 109: 170PubMedGoogle Scholar
  216. 216.
    Hootkins R, Fenves AZ, Stephens MK. Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature. Clin Nephrol 1989; 32(2): 75–8PubMedGoogle Scholar
  217. 217.
    Allon M, Lopez EJ, Min KW. Acute renal failure due to ciprofloxacin. Arch Intern Med 1990; 150: 2187–9PubMedCrossRefGoogle Scholar
  218. 218.
    Schlüter G. Ciprofloxacin: review of potential toxicologic effects. Am J Med 1987; 82 Suppl. 4A: 91–3Google Scholar
  219. 219.
    Zupancic M, Bukovec P. Complexation of magnesium (II) with ciprofloxacin and norfloxacin. Act Pharm 1996; 46: 221–8Google Scholar
  220. 220.
    Swanson BN, Boppana VK, Vlasses PH, et al. Norfloxacin disposition after sequentially increasing oral doses. Antimicrob Agents Chemother 1983; 23(2): 284–8PubMedCrossRefGoogle Scholar
  221. 221.
    Moesch C, Rincé M, Raby C, et al. Aminopenicillin crystalluria: identification by infrared spectrophotometry [in French]. Ann Biol Clin (Paris) 1985; 43(3): 227–31Google Scholar
  222. 222.
    Boffa JJ, De Preneuf H, Bouadma L, et al. Acute renal failure after amoxicillin crystallization [in French]. Presse Med 2000; 29(13): 699–701PubMedGoogle Scholar
  223. 223.
    Boursas M, Benhassine L, Kempf J, et al. Obstructive renal insufficiency caused by amoxicillin crystalluria [in French]. Ann Fr Anesth Reanim 1997; 16(7): 908–10PubMedCrossRefGoogle Scholar
  224. 224.
    Fogazzi GB, Cantu M, Saglimbeni L, et al. Amoxycillin, a rare but possible cause of crystalluria. Nephrol Dial Transplant 2003; 18(1): 212–4PubMedCrossRefGoogle Scholar
  225. 225.
    Menzi P. Furadantin-Stein in einer Ureterozele. Helvet Chir 1970; 37(4/5): 538–40Google Scholar
  226. 226.
    MacDonald JB, MacDonald ET. Nitrofurantoin crystalluria. BMJ 1976 Oct 30; II: 1044–5CrossRefGoogle Scholar
  227. 227.
    Pickens CL, Milliron AR, Fussner AL, et al. Abuse of guaifenesin-containing medications generates an excess of a carboxylate salt of beta-(2-methoxyphenoxy)-lactic acid, a guaifenesin metabolite, and results in urolithiasis. Urology 1999; 54(1): 23–7PubMedCrossRefGoogle Scholar
  228. 228.
    Assimos DG, Langenstroer P, Leinbach RF, et al. Guaifenesin-and ephedrine-induced stones. J Endourol 1999; 13(9): 665–7PubMedCrossRefGoogle Scholar
  229. 229.
    Blau JJ. Ephedrine nephrolithiasis associated with chronic ephedrine abuse. J Urol 1998; 160 (3 Pt 1): 825PubMedCrossRefGoogle Scholar
  230. 230.
    Powell T, Hsu FF, Turk J, et al. Ma-Huang strikes again: ephedrine nephrolithiasis. Am J Kidney Dis 1998; 32(1): 153–9PubMedCrossRefGoogle Scholar
  231. 231.
    Cate IV JC, Tenser R. Acute primidone overdose with massive crystalluria. Clin Toxicol 1975; 8(4): 385–9PubMedCrossRefGoogle Scholar
  232. 232.
    Lehmann DF. Primidone crystalluria following overdose: a report of a case and an analysis of the literature. Med Toxicol Adverse Drug Exp 1987; 2(5): 383–7PubMedCrossRefGoogle Scholar
  233. 233.
    Pitman SW, Frei E. Weekly methotrexate-calcium leukovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin’s lymphoma. Cancer Treat Rep 1977; 61: 695–701PubMedGoogle Scholar
  234. 234.
    Sand TE, Jacobsen S. Effect of urine pH and flow on renal clearance of methotrexate. Eur J Clin Pharmacol 1981; 19: 453–6PubMedCrossRefGoogle Scholar
  235. 235.
    Garnick MB, Mayer RJ, Abelson HT. Acute renal failure associated with cancer treatment. In: Brenner BM, Lazarus JM, editors. Acute renal failure. 2nd ed. New York: Churchill Livingstone, 1988: 636–45Google Scholar
  236. 236.
    Lenk S, Brien G, Bick C. Harnsteinbildung durch Dihydrotachysterol-Uberdosierung. Z Arztl Forbild 1970; 9: 470–1Google Scholar
  237. 237.
    Taylor WH. Renal calculi and self-medication with multivitamin preparations containing vitamin D. Clin Sci 1972; 42: 515–22PubMedGoogle Scholar
  238. 238.
    Pak CYC. Nephrolithiasis from calcium supplementation. J Urol 1987; 137: 1212–3PubMedGoogle Scholar
  239. 239.
    Jones G, Hogan DB, Yent DB, et al. Prevention and management of osteoporosis: consensus statements from scientific Advisory Board of the Osteoporosis Society of Canada. 8: vitamin D metabolites and analogs in the treatment of osteoporosis. CMAJ 1996; 155: 955–61Google Scholar
  240. 240.
    Oreopoulos DG, Silverberg S. Calcium oxalate urinary-tract stones in patients on maintenance dialysis. N Engl J Med 1974; 290(25): 1438–9PubMedGoogle Scholar
  241. 241.
    Caralps A, Lloveras J, Andreu J, et al. Urinary calculi in chronic dialysis patients. Lancet 1979; II(8150): 1024–5CrossRefGoogle Scholar
  242. 242.
    Oren A, Husdan H, Chen PT, et al. Calcium oxalate kidney stones in patients on continuous ambulatory peritoneal dialysis. Kidney Int 1984; 25(3): 534–8PubMedCrossRefGoogle Scholar
  243. 243.
    Daudon M, Lacour B, Jungers P, et al. Urolithiasis in patients with end-stage renal failure. J Urol 1992; 147: 977–80PubMedGoogle Scholar
  244. 244.
    Kass M, Kolker AE, Gordon M, et al. Acetazolamide and urolithiasis. Ophtalmology 1981; 88: 261–5Google Scholar
  245. 245.
    Wallace SJ. A comparative review of the adverse effects of anticonvulsants in children with epilepsy. Drug Saf 1996; 15(6): 378–93PubMedCrossRefGoogle Scholar
  246. 246.
    Willmore LJ. Choice and use of newer anticonvulsant drugs in older patients. Drugs Aging 2000; 17(6): 441–52PubMedCrossRefGoogle Scholar
  247. 247.
    Persky L, Chambers D, Potts A. Calculus formation and ureteral colic following acetazolamide therapy. JAMA 1956; 161: 1625–6CrossRefGoogle Scholar
  248. 248.
    Barraquer J, Escribano J. Colicos renales en el curso de tratamientos con acetazolamide. Rev Clin Esp 1957; 64: 310–3PubMedGoogle Scholar
  249. 249.
    Parfitt AM. Acetazolamide and sodium bicarbonate induced nephrocalcinosis and nephrolithiasis; relationship to citrate and calcium excretion. Arch Intern Med 1969; 124(6): 736–40PubMedCrossRefGoogle Scholar
  250. 250.
    Pepys MB. Acetazolamide and renal stone formation [letter]. Lancet 1970; I(7651): 837CrossRefGoogle Scholar
  251. 251.
    Parfitt AM. Acetazolamide and renal stone formation [letter]. Lancet 1970; II(7664): 153CrossRefGoogle Scholar
  252. 252.
    Roise O, Otnes B. Acetazolamide and renal calculi [in Norwegian]. Tidsskr Nor Laegeforen 1986; 106(1): 25–6PubMedGoogle Scholar
  253. 253.
    Rivalan J, Chevet D, Le Pogamp P, et al. Renal lithiasis, a logical complication of long-term treatment of glaucoma with a carbonic anhydrase inhibitor [in French]. Ann Med Interne (Paris) 1989; 140(5): 419–20Google Scholar
  254. 254.
    Tawil R, Moxley III RT, Griggs RC. Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders. Neurology 1993; 43(6): 1105–6PubMedCrossRefGoogle Scholar
  255. 255.
    Ellis PP. Urinary calculi with methazolamide therapy. Doc Ophthalmol 1973; 34: 137–42PubMedCrossRefGoogle Scholar
  256. 256.
    Carlsen J, Durcan J, Zabriskie N, et al. Nephrolithiasis with dorzolamide. Arch Ophthalmol 1999; 117(8): 1087–8PubMedCrossRefGoogle Scholar
  257. 257.
    Wallace MR, MacDiarmid J, Reeder J. Exacerbation of nephrolithiasis by a carbonic anhydrase inhibitor. N Z Med J 1974; 79(509): 687–90PubMedGoogle Scholar
  258. 258.
    Resor Jr SR, Resor LD. Chronic acetazolamide monotherapy in the treatment of juvenile myoclonic epilepsy. Neurology 1990; 40(11): 1677–81PubMedCrossRefGoogle Scholar
  259. 259.
    Parikh JR, Nolan RL. Acetazolamide-induced nephrocalcinosis. Abdom Imaging 1994; 19(5): 466–7PubMedCrossRefGoogle Scholar
  260. 260.
    Libenson MH, Kaye EM, Rosman NP, et al. Acetazolamide and furosemide for posthemorrhagic hydrocephalus of the newborn. Pediatr Neurol 1999; 20(3): 185–91PubMedCrossRefGoogle Scholar
  261. 261.
    Ahlstrand C, Tiselius HG. Urine composition and stone formation during treatment with acetazolamide. Scand J Urol Nephrol 1987; 21: 225–8PubMedCrossRefGoogle Scholar
  262. 262.
    Paisley KE, Tomson CR. Calcium phosphate stones during long-term acetazolamide treatment for epilepsy. Postgrad Med J 1999; 75(885): 427–8PubMedGoogle Scholar
  263. 263.
    Perucca E. A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res 1997; 35(4): 241–56PubMedCrossRefGoogle Scholar
  264. 264.
    Natsch S, Hekster YA, Keyser A, et al. Newer anticonvulsant drugs: role of pharmacology, drug interactions and adverse reactions in drug choice. Drug Saf 1997; 17(4): 228–40PubMedCrossRefGoogle Scholar
  265. 265.
    Glauser TA. Topiramate. Epilepsia 1999; 40 Suppl. 5: S71–80PubMedCrossRefGoogle Scholar
  266. 266.
    Saito Y, Yanagaki S, Oguni H, et al. Urolithiasis induced by combined ACTH and zonisamide treatment in a patient with startle induced epilepsy [in Japanese]. No To Hattatsu 2002; 34(5): 415–20PubMedGoogle Scholar
  267. 267.
    Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996; 37 Suppl. 2: S18–22PubMedCrossRefGoogle Scholar
  268. 268.
    Markind JE. Topiramate: a new antiepileptic drug. Am J Health Syst Pharm 1998; 55(6): 554–62PubMedGoogle Scholar
  269. 269.
    Takhar J, Manchanda R. Nephrolithiasis on topiramate therapy. Can J Psychiatry 2000; 45(5): 491–3PubMedGoogle Scholar
  270. 270.
    Daudon M, Réveillaud RJ, Rod D, et al. Piridoxilate-induced calcium oxalate nephrolithiasis: a nation-wide epidemiologic evaluation of incidence. In: Walker VR, Sutton RAL, Cameron ECB, et al., editors. Urolithiasis. New York: Plenum Press, 1989: 677–9Google Scholar
  271. 271.
    Daudon M, Réveillaud RJ, Jungers P. Piridoxilate-associated calcium oxalate urinary calculi: a new metabolic drug-induced nephrolithiasis [letter]. Lancet 1985; I(8441): 1338CrossRefGoogle Scholar
  272. 272.
    Wolf C, Maistre-Charransol G, Barthélémy C, et al. Iatrogenic oxalic lithiasis caused by piridoxilate [in French]. Nephrologie 1985; 6(5): 225–7PubMedGoogle Scholar
  273. 273.
    Vigeral P, Kenouch S, Chauveau D, et al. Piridoxilate-associated nephrocalcinosis: a new form of chronic oxalate nephropathy. Nephrol Dial Transplant 1987; 2(4): 275–8PubMedGoogle Scholar
  274. 274.
    Dequiedt P, Gosselin B, Benoit O, et al. Acute renal failure caused by acute oxalosis after massive ingestion of piridoxilate [in French]. Nephrologie 1985; 6(5): 228–30PubMedGoogle Scholar
  275. 275.
    Mousson C, Justrabo E, Rifle G, et al. Piridoxilate-induced oxalate nephropathy can lead to end-stage renal failure. Nephron 1993; 63(1): 104–6PubMedCrossRefGoogle Scholar
  276. 276.
    Hufnagle KG, Khan SN, Penn D, et al. Renal calcifications: a complication of long-term furosemide therapy in preterm infants. Pediatrics 1982; 70(3): 360–3PubMedGoogle Scholar
  277. 277.
    Venkataraman PS, Han BK, Tsang RC, et al. Secondary hyperparathyroidism and bone disease in infants receiving long-term furosemide therapy. Am J Dis Child 1983; 137(12): 1157–61PubMedGoogle Scholar
  278. 278.
    Glasier CM, Stoddard RA, Ackerman Jr NB, et al. Nephrolithiasis in infants: association with chronic furosemide therapy. Am J Roentgenol 1983; 140(1): 107–8Google Scholar
  279. 279.
    Noe HN, Bryant JF, Roy III S, et al. Urolithiasis in pre-term neonates associated with furosemide therapy. J Urol 1984; 132(1): 93–4PubMedGoogle Scholar
  280. 280.
    Gilsanz V, Fernal W, Reid BS, et al. Nephrolithiasis in premature infants. Radiology 1985; 154(1): 107–10PubMedGoogle Scholar
  281. 281.
    Myracle MR, McGahan JP, Goetzman BW, et al. Ultrasound diagnosis of renal calcification in infants on chronic furosemide therapy. J Clin Ultrasound 1986; 14(4): 281–7PubMedCrossRefGoogle Scholar
  282. 282.
    Ezzedeen F, Adelman RD, Ahlfors CE. Renal calcification in preterm infants: pathophysiology and long-term sequelae. J Pediatr 1988; 113(3): 532–9PubMedCrossRefGoogle Scholar
  283. 283.
    Itami N, Kawaguti M, Akutsu Y, et al. Renal calcifications in preterm infants [letter]. J Pediatr 1989; 114(6): 1068PubMedGoogle Scholar
  284. 284.
    Alon US, Scagliotti D, Garola RE. Nephrocalcinosis and nephrolithiasis in infants with congestive heart failure treated with furosemide. J Pediatr 1994; 125(1): 149–51PubMedCrossRefGoogle Scholar
  285. 285.
    Blickman JG, Herrin JT, Cleveland RH, et al. Coexisting nephrolithiasis and cholelithiasis in premature infants. Pediatr Radiol 1991; 21(5): 363–4PubMedCrossRefGoogle Scholar
  286. 286.
    Alon US. Nephrocalcinosis. Curr Opin Pediatr 1997; 9(2): 160–5PubMedCrossRefGoogle Scholar
  287. 287.
    Saarela T, Lanning P, Koivisto M, et al. Nephrocalcinosis in full-term infants receiving furosemide treatment for congestive heart failure: a study of the incidence and 2-year follow up. Eur J Pediatr 1999; 158: 668–72PubMedCrossRefGoogle Scholar
  288. 288.
    Kim YG, Kim B, Kim MK, et al. Medullary nephrocalcinosis associated with long-term furosemide abuse in adults. Nephrol Dial Transplant 2001; 16: 2303–9PubMedCrossRefGoogle Scholar
  289. 289.
    Levine DZ, Roy D, Tolnai G, et al. Chloride depletion and nephrocalcinosis. Am J Physiol 1974; 227: 878–83PubMedGoogle Scholar
  290. 290.
    Sidhu H, Hoppe B, Hesse A, et al. Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria. Lancet 1998; 352: 1026–9PubMedCrossRefGoogle Scholar
  291. 291.
    Sidhu H, Schmidt ME, Cornelius JG, et al. Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy. J Am Soc Nephrol 1999; 10: S334–40PubMedGoogle Scholar
  292. 292.
    Hokama S, Honma Y, Toma C, et al. Oxalate-degrading Enterococcus faecalis. Microbiol Immunol 2000; 44: 235–40PubMedGoogle Scholar
  293. 293.
    Campieri C, Campieri M, Bertuzzi V, et al. Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Int 2001; 60: 1097–105PubMedCrossRefGoogle Scholar
  294. 294.
    Golematis B, Hatzitheofilou C, Dreiling DA, et al. The incidence of urolithiasis in pepticulcer patients. Am J Gastroenterol 1977; 68: 367–71PubMedGoogle Scholar
  295. 295.
    Robson RH, Heading RC. Obsolete but dangerous antacid preparations. Postgrad Med J 1978; 54: 36–7PubMedCrossRefGoogle Scholar
  296. 296.
    Bloom WK, Flinchum D. Osteomalacia with pseudofractures caused by the ingestion of aluminum hydroxyde. JAMA 1960; 174: 1327–30CrossRefGoogle Scholar
  297. 297.
    Dent CE, Winter CS. Osteomalacia due to phosphate depletion from excess aluminum hydroxide ingestion. BMJ 1974; 1: 551–2PubMedCrossRefGoogle Scholar
  298. 298.
    Baker LR, Ackrill P, Cattel WR, et al. Iatrogenic osteomalacia and myopathy dueto phosphate depletion. BMJ 1974; 3: 150–2PubMedCrossRefGoogle Scholar
  299. 299.
    Cooke N, Teitelbaum S, Avioli LV. Antacid-induced osteomalacia and nephrolithiasis. Arch Intern Med 1978; 138: 1007–9PubMedCrossRefGoogle Scholar
  300. 300.
    Millette CH, Snodgrass GL. Acute renal failure associated with chronic antacid ingestion. Am J Hosp Pharm 1981; 38(9): 1352–5PubMedGoogle Scholar
  301. 301.
    Malek RS, Kelalis PP. Pediatric nephrolithiasis. J Urol 1975; 113: 545–51PubMedGoogle Scholar
  302. 302.
    Howard SC, Kaplan SD, Razzouk BI, et al. Urolithiasis in pediatric patients with acute lymphoblastic leukemia. Leukemia 2003; 17(3): 541–6PubMedCrossRefGoogle Scholar
  303. 303.
    Kamitsuka MD, Williams MA, Nyberg DA, et al. Renal calcification: a complication of dexamethasone therapy in preterm infants with bronchopulmonary dysplasia. J Perinatal 1995; 15(5): 359–63Google Scholar
  304. 304.
    Kumar N, Khwaja GA, Gupta M, et al. Antiepileptic drug induced osteomalacic myopathy with hyperparathyroidism and nephrolithiasis. J Assoc Physicians India 1993; 41(11): 748–9PubMedGoogle Scholar
  305. 305.
    Urivetzky M, Kessaris D, Smith AD. Ascorbic acid overdosing: a risk factor for calcium oxalate nephrolithiasis. J Urol 1992; 147: 1215–8PubMedGoogle Scholar
  306. 306.
    Smith LH. Risk of oxalate stone from large doses of vitamin C [letter]. N Engl J Med 1978; 298: 856Google Scholar
  307. 307.
    Auer BL, Auer D, Rodgers AL. Relative hyperoxaluria, crystalluria and haematuria after megadose ingestion of vitamin C. Eur J Clin Invest 1998; 28(9): 695–700PubMedCrossRefGoogle Scholar
  308. 308.
    Traxer O, Huet B, Poindexter J, et al. Effect of ascorbic acid consumption on urinary stone risk factors. J Urol 2003; 170 (2 Pt 1): 397–401PubMedCrossRefGoogle Scholar
  309. 309.
    Chalmers AH, Cowley DM, Brown JM. A possible etiological role for ascorbate in calculi formation. Clin Chem 1986; 32(2): 333–6PubMedGoogle Scholar
  310. 310.
    Curhan GC, Willett WC, Rimm EB, et al. A prospective study of the intake of vitamins C and B6, and the risk of kidney stones in men. J Urol 1996; 155: 1847–51PubMedCrossRefGoogle Scholar
  311. 311.
    Curhan GC, Willett WC, Speizer FE, et al. Intake of vitamins B6 and C and the risk of kidney stones in women. J Am Soc Nephrol 1999; 10(4): 840–5PubMedGoogle Scholar
  312. 312.
    Moesch C, Rincé M, Daudon M, et al. Renal intratubular crystallization of calcium oxalate and naftidrofuryl oxalate. Lancet 1991; 338: 1219–20PubMedCrossRefGoogle Scholar
  313. 313.
    Moesch C, Charmes JP, Bouthier F, et al. Calcium oxalate crystalluria in elderly patients and treatment with naftidrofuryl oxalate. Age Ageing 1995; 24(6): 464–7PubMedCrossRefGoogle Scholar
  314. 314.
    Retornaz F, Jean-Pastor MJ, Monestier S, et al. Recurrent calcium oxalate nephrolithiasis induced by naftidrofuryl oxalate [letter]. Nephron 2000; 85(1): 92PubMedCrossRefGoogle Scholar
  315. 315.
    Van der Niepen P, Janssen van Doorn K, Van den Houte K, et al. Nimesulide and acute renal failure caused by oxalate precipitation. Nephrol Dial Transplant 2002; 17: 315–22PubMedCrossRefGoogle Scholar
  316. 316.
    Thomas DW, Edwards JB, Gilligan JE, et al. Complications following intravenous administration of solutions containing xylitol. Med J Aust 1972; 1: 1238–46PubMedGoogle Scholar
  317. 317.
    Evans GW, Philips G, Mukherjee TM, et al. Identification of crystals deposited in brain and kidney after xylitol administration by biochemical, histochemical, and electron diffraction methods. J Clin Path 1973; 26: 32–6PubMedCrossRefGoogle Scholar
  318. 318.
    Dolp R, Paulini K. Oxalate formation by polytraumatized patients after parenteral nutrition with amino acids and xylitol [in German]. Int Z Vitam Ernahrungsforsch Beih 1976; 15: 228–33PubMedGoogle Scholar
  319. 319.
    Ludwig B, Schindler E, Bohl J, et al. Reno-cerebral oxalosis induced by xylitol. Neuroradiology 1984; 26: 517–21PubMedCrossRefGoogle Scholar
  320. 320.
    Frydl V. Cerebrorenal oxalate formation: a metabolic abnormality following parenteral infusions of carbohydrate exchange substances [in German]. Zentralbl Allg Pathol 1987; 133(4): 369–76PubMedGoogle Scholar
  321. 321.
    Dick WH, Lingeman JE, Preminger GM, et al. Laxative abuse as a cause for ammonium urate renal calculi. J Urol 1990; 143(2): 244–7PubMedGoogle Scholar
  322. 322.
    Soble JJ, Hamilton BD, Streem SB. Ammonium acid urate calculi: a reevaluation of risk factors. J Urol 1999; 161(3): 869–73PubMedCrossRefGoogle Scholar
  323. 323.
    Navas P, Grasset D. Anurie par lithiase urétérale urique bilatérale au cours d’un traitement par l’Amplivix. J Urol Néphrol 1973; 79: 466–9Google Scholar
  324. 324.
    Matzkies F. Wirkungen und Nebenwirkungen von Benz-bromaron bei der Initialbehandlung von Hyperurikämie und Gicht. Ergebnisse eines Feldversuches mit 3899 Patienten. Fortschr Med 1978; 96(32): 1619–21Google Scholar
  325. 325.
    McLain DA, Garriga FJ, Kantor OS. Adverse reactions associated with ticrynafen use. JAMA 1980; 243(8): 763–4PubMedCrossRefGoogle Scholar
  326. 326.
    Paddack GL, Wahl RC, Holman RE, et al. Acute renal failure associated with ticrynafen. JAMA 1980; 243(8): 764–5PubMedCrossRefGoogle Scholar
  327. 327.
    Richard O, Toupance O, Hublot C, et al. Factors affecting urinary lithogenesis following tienilic acid administration in man [in French]. Therapie 1981; 36(4): 429–34PubMedGoogle Scholar
  328. 328.
    Pfister B, Imhof P, Wirz H. Effect of sulphinpyrazone (Anturan) on uric acid excretion and plasma uric acid concentration in healthy volunteers. Eur J Clin Pharmacol 1978; 13(4): 263–5PubMedCrossRefGoogle Scholar
  329. 329.
    Hricik DE, Goldsmith GH. Uric acid nephrolithiasis and acute renal failure secondary to streptozotocin nephrotoxicity. Am J Med 1988; 84(1): 153–6PubMedCrossRefGoogle Scholar
  330. 330.
    Fam AG. Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient. Curr Rheumatol Rep 2001; 3(1): 29–35PubMedCrossRefGoogle Scholar

Copyright information

© adis data information BV 2004

Authors and Affiliations

  1. 1.CRISTAL Laboratory, Department of Biochemistry ANecker HospitalParisFrance
  2. 2.Department of NephrologyNecker HospitalParisFrance

Personalised recommendations